Bisphosphonate treatment and radiotherapy in metastatic breast cancer

Ural, Ali Uğur; Avcu, Ferit; Baran, Yusuf

doi:10.1007/s12032-008-9044-4

Cited by 14 publications

(7 citation statements)

References 45 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The development of CRC is a progressive process comprising genetic changes in tumour-suppressor genes and oncogenes [15, 16]. Many genetic alterations have been reported to be associated with the development of CRC.…”

Section: Discussionmentioning

confidence: 99%

Cysteine-Rich Intestinal Protein 1 Silencing Inhibits Migration and Invasion in Human Colorectal Cancer

Zou

Zhou

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Cysteine-rich intestinal protein 1 (CRIP1), a member of the LIM/double zinc finger protein family, is abnormally expressed in several tumour types. However, few data are available on the role of CRIP1 in cancer. In the present study, we aimed to investigate the expression profile and functions of CRIP1 in colorectal cancer. Methods: To examine the protein expression level of CRIP1, immunohistochemistry (IHC) was performed on 56 pairs of colon cancer tissue samples. Western blotting was performed to investigate CRIP1 protein expression in four colon cancer cell lines. The endogenous expression of CRIP1 was suppressed using short interfering RNAs (siRNAs). Cell proliferation assays were used to determine whether CRIP1 silencing affected cell proliferation. Flow cytometry analysis was used to detect cell apoptosis. The effects of silencing CRIP1 on cell migration and invasion was detected using the transwell and wound-healing assays. Results: IHC analysis showed that protein level of CRIP1 was significantly higher in tumour tissue samples than in paired non-tumour tissue samples and that the CRIP1 level was higher in metastatic tissue samples than in non-metastatic tissue samples. In addition, protein levels of CRIP1 were higher in highly metastatic colon cancer cell lines than in colon cancer cell lines with low metastasis. Further, CRIP1 silencing had no effect on cell proliferation or apoptosis in SW620 and HT29 cells. CRIP1 silencing suppressed cell migration and invasion obviously in SW620 and HT29 cells. Conclusion: The present study provides new evidence that abnormal expression of CRIP1 might be related to the degree of metastasis in colorectal cancer and that CRIP1 silencing could effectively inhibit migration and invasion during colorectal cancer development. These findings might aid the development of a biomarker for colon cancer prognosis and metastasis, and thus help to treat this common type of cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Cysteine-Rich Intestinal Protein 1 Silencing Inhibits Migration and Invasion in Human Colorectal Cancer

Zou

Zhou

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…For diffuse bone pain resulting from metastases, bisphosphonates, glucocorticoids, or systemic administration of radioisotopes should be considered. For localized bone pain, external-beam radiation therapy or nerve block (e.g., for rib pain) may be helpful [23][24][25][26][27]. For treatment of refractory pain, interventional procedures such as regional infusions with the insertion of an infusion pump, percutaneous kyphoplasty or vertebroplasty, and radiofrequency ablation are potential treatment options [22].…”

Section: Painmentioning

confidence: 99%

Symptom Management in Metastatic Breast Cancer

2011

View full text Add to dashboard Cite

Approximately 40,000 women die as a result of breast cancer each year and many more live with advanced disease. When breast cancer recurs, the goals of treatment often shift from one of cure to controlling the disease for as long as possible while palliating symptoms interfering with the patient's functional status and quality of life. This requires ongoing discussions with the patient and family about the goals of care. Many symptoms depend on the site of metastasis, with bone being the most frequent, and commonly occur with fatigue, depression, insomnia, and pain. The purpose of this paper is to identify and provide an overview of the management of the most common symptoms in patients with breast cancer metastases.

show abstract

“…Whilst radiotherapy certainly mediates some analgesic effect via tumor debulking, there is also evidence pointing towards osteoclast inhibition. 91 Given the potential overlap of the mechanisms of radiotherapy and bisphosphonates, and availability of in vivo evidence, there is growing interest in combining the two treatments for synergistic effect. 88,91 More recently, bone-seeking radiopharmaceuticals have been developed for palliation of refractory bone pain.…”

Section: Managing Bone Pain As An Established Skeletal Related Complimentioning

confidence: 99%

“…91 Given the potential overlap of the mechanisms of radiotherapy and bisphosphonates, and availability of in vivo evidence, there is growing interest in combining the two treatments for synergistic effect. 88,91 More recently, bone-seeking radiopharmaceuticals have been developed for palliation of refractory bone pain. These are thought to act as a substitution for the hydroxyapatite of bone, with more uptake in osteoblastic metastases where new reactive bone is formed.…”

Section: Managing Bone Pain As An Established Skeletal Related Complimentioning

confidence: 99%

Optimal management of bone metastases in breast cancer patients

Wong

Pavlakis

2011

BCTT

View full text Add to dashboard Cite

Bone metastasis in breast cancer is a significant clinical problem. It not only indicates incurable disease with a guarded prognosis, but is also associated with skeletal-related morbidities including bone pain, pathological fractures, spinal cord compression, and hypercalcemia. In recent years, the mechanism of bone metastasis has been further elucidated. Bone metastasis involves a vicious cycle of close interaction between the tumor and the bone microenvironment. In patients with bone metastases, the goal of management is to prevent further skeletal-related events, manage complications, reduce bone pain, and improve quality of life. Bisphosphonates are a proven therapy for the above indications. Recently, a drug of a different class, the RANK ligand antibody, denosumab, has been shown to reduce skeletal-related events more than the bisphosphonate, zoledronic acid. Other strategies of clinical value may include surgery, radiotherapy, radiopharmaceuticals, and, of course, effective systemic therapy. In early breast cancer, bisphosphonates may have an antitumor effect and prevent both bone and non-bone metastases. Whilst two important Phase III trials with conflicting results have led to controversy in this topic, final results from these and other key Phase III trials must still be awaited before a firm conclusion can be drawn about the use of bisphosphonates in this setting. Advances in bone markers, predictive biomarkers, multi-imaging modalities, and the introduction of novel agents have ushered in a new era of proactive management for bone metastases in breast cancer.

show abstract

Bisphosphonate treatment and radiotherapy in metastatic breast cancer

Cited by 14 publications

References 45 publications

Cysteine-Rich Intestinal Protein 1 Silencing Inhibits Migration and Invasion in Human Colorectal Cancer

Cysteine-Rich Intestinal Protein 1 Silencing Inhibits Migration and Invasion in Human Colorectal Cancer

Symptom Management in Metastatic Breast Cancer

Optimal management of bone metastases in breast cancer patients

Contact Info

Product

Resources

About